These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30168386)

  • 1. A Pilot Study Characterizing Factors in Adherence to Cutaneous Lupus Treatment.
    Ro T; Tull RZ; Cardwell LA; Farhangian ME; Moustafa F; Richardson I; Jorizzo JL; Feldman S; Huang W
    J Cutan Med Surg; 2018; 22(5):530-532. PubMed ID: 30168386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin.
    Richardson TT; Cohen PR
    Cutis; 2000 Sep; 66(3):183-8. PubMed ID: 11006852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
    Kuhn A; Aberer E; Bata-Csörgő Z; Caproni M; Dreher A; Frances C; Gläser R; Klötgen HW; Landmann A; Marinovic B; Nyberg F; Olteanu R; Ranki A; Szepietowski JC; Volc-Platzer B
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):389-404. PubMed ID: 27859683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.
    Kuhn A; Landmann A; Patsinakidis N; Ruland V; Nozinic S; Perusquía Ortiz AM; Sauerland C; Luger T; Tsianakas A; Bonsmann G
    Lupus; 2016 Oct; 25(12):1357-64. PubMed ID: 27147621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cutaneous manifestations of lupus erythematosus: A systematic review.
    Fairley JL; Oon S; Saracino AM; Nikpour M
    Semin Arthritis Rheum; 2020 Feb; 50(1):95-127. PubMed ID: 31526594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy.
    Roenigk HH; Martin JS; Eichorn P; Gilliam JN
    Cutis; 1980 Mar; 25(3):281-5. PubMed ID: 6987043
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of cutaneous lupus.
    Chang AY; Werth VP
    Curr Rheumatol Rep; 2011 Aug; 13(4):300-7. PubMed ID: 21503694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.
    Tzellos TG; Kouvelas D
    Eur J Clin Pharmacol; 2008 Apr; 64(4):337-41. PubMed ID: 18157526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
    Avgerinou G; Papafragkaki DK; Nasiopoulou A; Arapaki A; Katsambas A; Stavropoulos PG
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):762-7. PubMed ID: 21707772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenetics of cutaneous lupus erythematosus.
    Hersh AO; Arkin LM; Prahalad S
    Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pearl: discoid lupus erythematosus--treatment with occlusive compression.
    Maggio KL; Singer MT; James WD
    J Am Acad Dermatol; 1996 Oct; 35(4):627-8. PubMed ID: 8859295
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnostic approach and treatment of cutaneous lupus erythematosus.
    Sticherling M; Bonsmann G; Kuhn A
    J Dtsch Dermatol Ges; 2008 Jan; 6(1):48-59. PubMed ID: 18190433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus.
    Sigges J; Biazar C; Landmann A; Ruland V; Patsinakidis N; Amler S; Bonsmann G; Kuhn A;
    Autoimmun Rev; 2013 May; 12(7):694-702. PubMed ID: 23220353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized.
    Farhangian ME; Huang WW; Feldman SR
    Dermatol Ther (Heidelb); 2015 Jun; 5(2):91-105. PubMed ID: 25899142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the evidence and cost of therapies for cutaneous lupus erythematosus.
    Rosen JD; Paul S; Maderal A
    Lupus; 2019 Jun; 28(7):799-805. PubMed ID: 31042129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative management of lupus erythematosus.
    Knott HM; Martínez JD
    Dermatol Clin; 2010 Jul; 28(3):489-99. PubMed ID: 20510759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.